Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.786
Revised: August 19, 2013
Accepted: August 28, 2013
Published online: January 21, 2014
Core tip: The study provides information on the clinical characteristics and laboratory findings that predict survival in patients with hepatocellular carcinoma and established cirrhosis treated with sorafenib. This group of patients is particularly fragile and difficult to treat, and therapy with systemic agents, including sorafenib, requires careful monitoring. We report that parameters related to the tumor (extrahepatic spread, vascular invasion), common laboratory tests (alpha-fetoprotein or alkaline phosphatase) and patients characteristics (performance status) are significant predictors of overall survival in this group. These data provide important clinical information for the management of this type of patients.